Search

Your search keyword '"Nakamura, Ryotaro"' showing total 13 results
Start Over Author "Nakamura, Ryotaro" Journal american journal of hematology
13 results on '"Nakamura, Ryotaro"'

1. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia

Author

Othman, Tamer, primary, Li, Shanpeng, additional, Zhang, Jianying, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Ngo, Dat, additional, Chen, Jason, additional, Farol, Leonardo, additional, Sahebi, Firoozeh, additional, Sandhu, Karamjeet, additional, Spielberger, Ricardo, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Stein, Anthony S., additional, Nakamura, Ryotaro, additional, Pullarkat, Vinod, additional, Mei, Matthew, additional, Aldoss, Ibrahim, additional, and Koller, Paul, additional

Published
2024
Full Text
View/download PDF

2. High Response Rates and Transition to Transplant after Novel Targeted and Cellular Therapies in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia with Philadelphia‐Like Fusions

Author

Aldoss, Ibrahim, primary, Afkhami, Michelle, additional, Yang, Dongyun, additional, Gu, Zhaohui, additional, Mokhtari, Sally, additional, Shahani, Shilpa, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Koller, Paul, additional, Arslan, Shukaib, additional, Tomasian, Vanina, additional, Al Malki, Monzr M., additional, Artz, Andrew, additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Ball, Brian, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Becker, Pamela S., additional, Stewart, Forrest M., additional, Curtin, Peter, additional, Smith, Eileen, additional, Telatar, Milhan, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Nakamura, Ryotaro, additional, and Pullarkat, Vinod, additional

Published
2023
Full Text
View/download PDF

3. Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus‐specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis

Author

La Rosa, Corinna, primary, Aldoss, Ibrahim, additional, Park, Yoonsuh, additional, Yang, Dongyun, additional, Zhou, Qiao, additional, Gendzekhadze, Ketevan, additional, Kaltcheva, Teodora, additional, Rida, Wasima, additional, Dempsey, Shannon, additional, Arslan, Shukaib, additional, Artz, Andrew, additional, Ball, Brian, additional, Nikolaenko, Liana, additional, Pullarkat, Vinod A., additional, Nakamura, Ryotaro, additional, and Diamond, Don J., additional

Published
2023
Full Text
View/download PDF

4. Health‐related quality of life in reduced‐intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: BMT CTN 1102

Author

Cusatis, Rachel, primary, Martens, Michael J., additional, Nakamura, Ryotaro, additional, Cutler, Corey S., additional, Saber, Wael, additional, Lee, Stephanie J., additional, Logan, Brent R., additional, Shaw, Bronwen E., additional, Gregory, Alyssa, additional, D'Souza, Anita, additional, Hamilton, Betty K., additional, Horowitz, Mary M., additional, and Flynn, Kathryn E., additional

Published
2022
Full Text
View/download PDF

5. Adoptive transfer of functional SARS‐COV ‐2‐specific immunity from donor graft to hematopoietic stem cell transplant recipients

Author

La Rosa, Corinna, primary, Chiuppesi, Flavia, additional, Park, Yoonsuh, additional, Gendzekhadze, Ketevan, additional, Zhou, Qiao, additional, Faircloth, Katelyn, additional, Kaltcheva, Teodora, additional, Johnson, Daisy, additional, Ortega Francisco, Sandra, additional, Amanam, Idoroenyi, additional, Otoukesh, Salman, additional, Pullarkat, Vinod A., additional, Nakamura, Ryotaro, additional, Diamond, Don J., additional, Forman, Stephen J., additional, and Al Malki, Monzr M., additional

Published
2022
Full Text
View/download PDF

8. High prevalence and inferior long‐term outcomes for TP53 mutations in therapy‐related acute lymphoblastic leukemia

Author

Pourhassan, Hoda, primary, Yang, Dongyun, additional, Afkhami, Michelle, additional, Pillai, Raju, additional, Ball, Brian, additional, Al Malki, Monzr, additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Artz, Andrew, additional, Curtin, Peter, additional, Armenian, Saro, additional, Stein, Anthony, additional, Forman, Stephen J., additional, Marcucci, Guido, additional, Pullarkat, Vinod, additional, Nakamura, Ryotaro, additional, and Aldoss, Ibrahim, additional

Published
2022
Full Text
View/download PDF

9. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax ( HMA‐Ven ) or liposomal daunorubicin‐cytarabine ( CPX ‐351)

Author

Salhotra, Amandeep, primary, Aribi, Ahmed, additional, Ngo, Dat, additional, Zhang, Jianying, additional, Sandhu, Karamjeet, additional, Al‐Malki, Monzr, additional, Ali, Haris, additional, Koller, Paul, additional, Arslan, Shukaib, additional, Budde, Elizabeth, additional, Khaled, Samer, additional, Dadwal, Sanjeet, additional, Snyder, David S., additional, Artz, Andrew, additional, Forman, Stephen, additional, Nakamura, Ryotaro, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Aldoss, Ibrahim, additional, and Pullarkat, Vinod, additional

Published
2021
Full Text
View/download PDF

10. Venetoclax and hypomethylating agents inFLT3‐mutated acute myeloid leukemia

Author

Aldoss, Ibrahim, primary, Zhang, Jianying, additional, Mei, Matthew, additional, Al Malki, Monzr M, additional, Arslan, Shukaib, additional, Ngo, Dat, additional, Aribi, Ahmed, additional, Ali, Haris, additional, Sandhu, Karamjeet, additional, Salhotra, Amandeep, additional, Koller, Paul, additional, Khaled, Samer, additional, Artz, Andrew, additional, Snyder, David, additional, Nakamura, Ryotaro, additional, Forman, Stephen J, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, and Pullarkat, Vinod, additional

Published
2020
Full Text
View/download PDF

11. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Author

Aldoss, Ibrahim, primary, Yang, Dongyun, additional, Pillai, Raju, additional, Sanchez, James F., additional, Mei, Matthew, additional, Aribi, Ahmed, additional, Ali, Haris, additional, Sandhu, Karamjeet, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Khaled, Samer, additional, Sun, Weili, additional, O'Donnell, Margaret, additional, Snyder, David, additional, Nakamura, Ryotaro, additional, Stein, Anthony S., additional, Forman, Stephen J., additional, Marcucci, Guido, additional, and Pullarkat, Vinod, additional

Published
2019
Full Text
View/download PDF

13. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Author

Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, and Mei M

Subjects
Humans, Male, Female, Middle Aged, Adult, Retrospective Studies, Aged, Maintenance Chemotherapy, Philadelphia Chromosome, Pyridazines therapeutic use, Pyridazines adverse effects, Pyridazines administration & dosage, Imatinib Mesylate therapeutic use, Imatinib Mesylate adverse effects, Imatinib Mesylate administration & dosage, Imidazoles adverse effects, Imidazoles administration & dosage, Imidazoles therapeutic use, Young Adult, Transplantation, Homologous, Adolescent, Tyrosine Kinase Inhibitors, Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage
Abstract

Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post-HCT, but published clinical experience is primarily with the first-generation TKI imatinib while data with newer generation TKIs are limited. We conducted a retrospective analysis of 185 Ph+ ALL patients who underwent HCT followed by TKI maintenance from 2003 to 2021 at City of Hope. Initially, 50 (27.0%) received imatinib, 118 (63.8%) received a second-generation TKI (2G-TKI), and 17 (9.2%) received ponatinib. A total of 77 patients (41.6%) required a dose reduction of their initial TKI due to toxicity. Sixty-six patients (35.7%) did not complete maintenance due to toxicity; 69 patients (37.3%) discontinued 1 TKI, and 11 (5.9%) discontinued 2 TKIs due to toxicity. Initial imatinib versus 2G-TKI versus ponatinib maintenance was discontinued in 19 (38.0%) versus 68 (57.6%) versus 3 (17.6%) patients due to toxicity (p = .003), respectively. Patients on ponatinib as their initial TKI had a longer duration of TKI maintenance versus 2G-TKI: 576.0 days (range, 72-921) versus 254.5 days (range, 3-2740; p = .02). The most common reasons for initial TKI discontinuation include gastrointestinal (GI) intolerance (15.1%), cytopenia (8.6%), and fluid retention (3.8%). The 5-year overall survival and progression-free survival for the total population were 78% and 71%, respectively. Our findings demonstrate the challenges of delivering post-HCT TKI maintenance in a large real-world cohort as toxicities leading to TKI interruptions, discontinuation, and dose reduction were common., (© 2024 Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results